Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02508649 · ClinicalTrials.gov registry record · Phase 2
Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial
A Phase 2 study, sponsored by Ferring Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 868
- Enrollment target
NCT02508649 is a Phase 2 study that was terminated before completion, run by Ferring Pharmaceuticals. The registered enrollment target is 868 participants.
The verdict
NCT02508649, a Phase 2 study, was terminated before completion, sponsored by Ferring Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 868 participants
- Enrollment target
Study Summary
This is a double-blind, randomised, placebo-controlled, two-part adaptive clinical trial. The trial is designed to investigate the efficacy and safety of multiple dosing regimens of selepressin and to confirm the efficacy and safety of one dosing regimen in treatment of adult patients with septic shock requiring vasopressor.
Interventions
- DRUG placebo
- DRUG selepressin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 868 participants |
| Start Date | 2015-07 |
| Est. Completion | 2018-02-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02508649
The ClinicalTrials.gov registry entry for NCT02508649 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 868 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02508649 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02508649 about?
NCT02508649 is a clinical study titled "Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial". This is a double-blind, randomised, placebo-controlled, two-part adaptive clinical trial. The trial is designed to investigate the efficacy and safety of multiple dosing regimens of selepressin and to confirm the efficacy and safety of one dosing regimen in treatment of adult patients with septic sh...
What is the current status of trial NCT02508649?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 868 participants. The study started on 2015-07. Estimated completion is 2018-02-26.
What interventions are being tested in trial NCT02508649?
The interventions under investigation include: placebo (DRUG), selepressin (DRUG).
Who is sponsoring clinical trial NCT02508649?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.